Новости

PJ Barnes-small

Гиганти в торакалната медицина: Питър Барнс

Giants in Chest Medicine Peter J. Barnes, MA, DM, DSc, Master FCCP   Editor’s Note: This series recognizes and highlights the accomplishments of individuals who have contributed greatly to chest medicine. To view the video interview with Dr Barnes, go to journal. publications.chestnet.org Chance may have led Peter J. Barnes, MA, DM, DSc, Master FCCP, / прочети повече

Международни препоръки за диагноза, оценка и терапия на тежка астма

Лечението на тежката или устойчива на терапия астма все повече се признава като проблем, по който няма задоволителни решения. Сформираната група от специалисти, подкрепена от Европейското респираторно дружество и Американското торакално общество, направи обобщение на дефинициите и даде препоръки и насоки за оценка и лечение на тежка астма при деца и възрастни. Извършеният преглед на / прочети повече

Безопасност на β2-агонисти: приключва ли 50-годишният дебат?

Safety of b2-agonists: a 50-year debate closed?   Jean Bousquet1,2, Arnaud Bourdin1,3 and Pascal Demoly4   Affiliations: 1University Hospital, Hospital Arnaud de Villeneuve, Dept of Respiratory Diseases, Montpellier, 2Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Respiratory and Environmental Epidemiology team, Villejuif, 3Inserm U1046, Montpellier University 1 and 2, Montpellier, and 4Allergy / прочети повече

Антибиотици при екзацербации на ХОББ

Antibiotics for Acute and Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease   Marc Miravitlles1 and Antonio Anzueto2   1Pneumology Department, Hospital Universitari Vall d’Hebron, Centro de Investigacio´n Biome´dica en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; and 2Division of Pulmonary Diseases/Critical Care Medicine, Department of Medicine, University of Texas Health Science Center / прочети повече

Теофилин при астма и ХОББ

Theophylline   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 188 2013   Theophylline (dimethylxanthine) has been used to treat airway diseases for more than 80 years. It was originally used as a bronchodilator, but the relatively high doses required are associated with frequent side effects, so its use declined as inhaled b2-agonists became / прочети повече

Утвърдена и експериментална медикаментозна терапия на белодробна саркоидоза

Established and experimental medical therapy of pulmonary sarcoidosis   Eur Respir J 2013; 41: 1424–1438   ABSTRACT: The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As new treatments have been introduced, the best way to assess and compare treatments remains unknown. The goal of this review is to discuss the / прочети повече

Pulmonary Necrotizing Granulomas of Unknown Cause

CHEST 2013; 144(3):813–824   Clinical and Pathologic Analysis of 131 Patients With Completely Resected Nodules   Background: The cause of pulmonary necrotizing granulomas is often unclear, even after histologic examination. Our aim was to determine the clinical signifi cance of histologically unexplained necrotizing granulomas. Methods: Pulmonary necrotizing granulomas surgically resected at the Mayo Clinic (1994-2004) / прочети повече

Резултати от национално скринингово проучване върху рак на белия дроб

Results of the Two Incidence Screenings in the National Lung Screening Trial   T h e new engl and journa l o f medicine n engl j med 369;10 nejm.org 920 september 5, 2013   Background The National Lung Screening Trial was conducted to determine whether three an- nual screenings (rounds T0, T1, and T2) / прочети повече

Препоръки за диагноза, лечение и превенция на нетуберкулозни микобактериални инфекции

An Official  ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases   This  Official Statement of the American Thoracic Society  (ATS)  and the Infectious Diseases Society  of America (IDSA) was  adopted by the ATS Board Of  Directors, September  2006, and by the IDSA  Board of Directors, January 2007   SUMMARY   Diagnostic Criteria of / прочети повече

Продължително макролидно лечение при хронично белодробно заболяване

Long-term macrolide treatment for chronic respiratory disease   Eur Respir J 2013; 42: 239–251 | DOI: 10.1183/09031936.00136712   Long-term macrolide treatment was first shown to alter the natural history of diffuse panbronchiolitis (DPB) in the late 1980s. Since then, macrolides have been demonstrated to exert antiinflammatory and immunomodulatory activity in addition to being antimicrobial. Indeed, / прочети повече